Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 27;2025(1):e240115.
doi: 10.1530/EDM-24-0115. Print 2025 Jan 1.

Levothyroxine malabsorption following sleeve gastrectomy

Affiliations

Levothyroxine malabsorption following sleeve gastrectomy

Elodie Gruneisen et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Summary: Oral levothyroxine (LT4) is prescribed worldwide for hypothyroidism. Bariatric surgery for patients with obesity has shown a substantial, long-term weight loss and considerable improvement of obesity-related diseases. LT4 malabsorption represents a significant cause of refractory hypothyroidism, well known after malabsorptive bariatric surgery such as Roux-en-Y gastric bypass. However, few studies have shown an increase in oral LT4 needed after sleeve gastrectomy. We present a 47-year-old woman with class III obesity and a history of papillary thyroid cancer, with an excellent biochemical and structural response after total thyroidectomy and radioactive iodine. She underwent sleeve gastrectomy 3 years later and developed refractory hypothyroidism despite taking high doses of oral LT4 and ensuring compliance. The T4 absorption test confirmed gastrointestinal LT4 malabsorption. She was initiated on intramuscular LT4 and oral T3 (liothyronine) with improving symptoms and levels of thyroid-stimulating hormone.

Learning points: Monitoring thyroid function tests is essential after bariatric surgery, including sleeve gastrectomy. Oral LT4 malabsorption should be considered in cases of refractory hypothyroidism. The T4 absorption test is a useful tool for distinguishing true malabsorption from pseudo-malabsorption. Decreased LT4 absorption after bariatric surgery might be explained by higher gastric pH and reduced stomach volume (impaired dissolution) and by interference with food, vitamin/mineral supplements or other drugs. When LT4 malabsorption is confirmed, a trial of other oral formulations (LT4 tablet crushed, soft gel or liquid preparation) or parenteral administrations is suggested.

Keywords: gastrectomy; levothyroxine; malabsorption; metabolism; sleeve.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

    1. Azran C, Porat D, Fine-Shamir N, et al. . Oral levothyroxine therapy postbariatric surgery: biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis 2019. 15 333–341. (10.1016/j.soard.2019.01.001) - DOI - PubMed
    1. Welbourn R, Hollyman M, Kinsman R, et al. . Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the fourth IFSO global registry report 2018. Obes Surg 2019. 29 782–795. (10.1007/s11695-018-3593-1) - DOI - PubMed
    1. Biertho L, Hong D & Gagner M. Bariatric Surgery: Surgical Options and Outcomes. In:. Canadian Adult Obesity Clinical Practice Guidelines 2020. (https://obesitycanada.ca/guidelines/surgeryoptions)
    1. Mingrone G, Panunzi S, De Gaetano A, et al. . Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2021. 397 293–304. (10.1016/s0140-6736(20)32649-0) - DOI - PubMed
    1. Currie AC, Kaur V, Carey I, et al. . Obstructive sleep apnea remission following bariatric surgery: a national registry cohort study. Surg Obes Relat Dis 2021. 17 1576–1582. (10.1016/j.soard.2021.05.021) - DOI - PubMed

LinkOut - more resources